FARMINGDALE, N.Y., Dec. 12, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has announced the termination of its distribution agreement with Aesculap, Inc., for the Misonix BoneScalpel™ Ultrasonic Bone Cutting System.
Since January 2011, Aesculap has been a non-exclusive, private label distributor of the BoneScalpel in the United States, for clinical applications in spine surgery and cranial surgery. Under the non-exclusive distribution agreement, Aesculap retains the right to sell BoneScalpel disposables to certain, limited hospital accounts, post termination, which are covered by binding supply agreements for varying periods of time, but not to exceed 3 years. An additional aspect of the cancellation requires Misonix to purchase all hardware inventory in Aesculap's possession. This inventory will feature prominently in the Company's plans to support its rapidly growing, proprietary sales organization with equipment for sales, demonstration and evaluation purposes.
Consistent with its business strategy, Misonix is committed to creating brand equity by selling its products under its own label via its own proprietary sales organization. Misonix, to date, has appointed and trained upwards of 40 independent sales agencies, with more than 200 salespeople, to market its BoneScalpel product line to neurosurgeons, spine surgeons, orthopedic surgeons and cranio maxillo-facial surgeons, backed by its own sales & marketing management team.
The BoneScalpel is a novel ultrasonic osteotome used for safe, tissue-selective bone dissection that encourages en-bloc bone removal and refined osteotomies while sparing elastic soft tissue structures.
|SOURCE Misonix, Inc.|
Copyright©2012 PR Newswire.
All rights reserved